Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin. 

HSCT patients at high risk of developing vitiligo

3 months ago

Patients who underwent haematopoietic stem cell transplantation (HSCT) develop vitiligo at a significantly higher rate than controls, according to a new study. Moreover, allogeneic HSCT and bone marrow-sourced stem cells are independently tied to increased risk of developing vitiligo after HSCT.

Researchers conducted a nationwide, population-based cohort study using the Korean National Health Insurance Claims Database from 2009 to 2013 to assess the incidence and risk factors of subsequent vitiligo after HSCT.

Included in the HSCT recipient group (n=2,747) were those who had undergone the procedure between 2010 and 2011, as well as those who had not undergone treatment for vitiligo in 2009 (to exclude pre-existing active vitiligo). Also, an age- and sex-matched control group (n=8,241) without HSCT was established.

Between 2010 and 2013, 1.06 percent of patients in the HSCT recipient group had newly acquired vitiligo. Additionally, a significant increase in vitiligo cases was seen in HSCT recipients (odds ratio [OR], 3.130; 95 percent CI, 1.859 to 5.271) compared with controls (0.34 percent).

Allogeneic HSCT (OR, 5.593; 1.628 to 19.213) and bone marrow-sources stem cells (as compared with peripheral blood-sources stem cells; OR, 2.942; 1.114 to 5.576) were independent risk factors of vitiligo occurrence after HSCT.

In a different study, recipients of allogeneic HSCT were found to have an elevated risk of developing basal cell carcinoma (hazard ratio [HR], 3.1; 1.9 to 5.2), squamous cell carcinoma (HR, 18.3; 4.1 to 81.8) and malignant melanoma (HR, 5.5; 1.7 to 17.1). This finding highlighted the need for dermatologic follow-up in HSCT recipients. [JAMA Dermatol 2016 ;152:177-83]

The current study was limited by the unavailability of medical record review, according to researchers.

Editor's Recommendations
Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.